SpinalCyte was issued Australian Patent No. 2013299505, “Generation of Cartilage Ex Vivo from Fibroblasts.”
The patent addresses use of mechanical stress in an ex vivo, low oxygen environment to produce chondrocytes that support cartilage regrowth. The patent also covers an imaging device to design and develop a mold upon which new cartilage can grow.
SpinalCyte’s patent portfolio now includes 22 U.S. and foreign patents issued and directly owned by the company, with 44 patents pending.
The company’s CybroCell fibroblasts are part of an ongoing clinical trial, investigating use in spinal disc regeneration.
SpinalCyte was issued Australian Patent No. 2013299505, “Generation of Cartilage Ex Vivo from Fibroblasts.”
The patent addresses use of mechanical stress in an ex vivo, low oxygen environment to produce chondrocytes that support cartilage regrowth. The patent also covers an imaging device to design and develop a mold upon which new...
SpinalCyte was issued Australian Patent No. 2013299505, “Generation of Cartilage Ex Vivo from Fibroblasts.”
The patent addresses use of mechanical stress in an ex vivo, low oxygen environment to produce chondrocytes that support cartilage regrowth. The patent also covers an imaging device to design and develop a mold upon which new cartilage can grow.
SpinalCyte’s patent portfolio now includes 22 U.S. and foreign patents issued and directly owned by the company, with 44 patents pending.
The company’s CybroCell fibroblasts are part of an ongoing clinical trial, investigating use in spinal disc regeneration.
Copy to clipboard 
